(thirdQuint)AMPLIFY - D6571C00001 Duaklir USA Phase III Study.

 This study was conducted to assess the bronchodilator efficacy and safety as well as effect on health related quality of life of AB/FF 400/12 1/2g compared to the individual components (AB 400 1/2g and FF 12 1/2g) in COPD patients.

 The trial duration of 24 weeks allows the assessment of the effect on symptoms improvement of the combined treatments versus individual components as well as the long term bronchodilation comparison between AB 400 1/2g and TIO 18 1/2g in minimizing the risk of COPD exacerbations in current or former smokers, aged 40 in symptomatic COPD patients.

.

 AMPLIFY - D6571C00001 Duaklir USA Phase III Study@highlight

This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 4001/2g/Formoterol Fumarate (AB/FF) 12 1/2g compared to individual components and TIO (Tiotropium) 18 1/2g when administered to patients with stable chronic obstructive pulmonary disease (COPD).

